Overview of Dr. Paik
Dr. Paul Paik is an oncologist in New York, NY and is affiliated with Memorial Sloan-Kettering Cancer Center. He received his medical degree from Weill Cornell Medicine and has been in practice 12 years. Dr. Paik accepts several types of health insurance, listed below. He is one of 468 doctors at Memorial Sloan-Kettering Cancer Center who specialize in Oncology. He has more than 90 publications and over 500 citings.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2005 - 2008
Weill Cornell MedicineClass of 2005
Certifications & Licensure
FL State Medical License 2021 - Present
NY State Medical License 2008 - 2025
NJ State Medical License 2018 - 2025
- American Board of Internal Medicine Medical Oncology
Clinical Trials
Publications & Presentations
PubMed
- 1 citations
Initial Chemotherapy for Locally Advanced and Metastatic NUT Carcinoma.
Luo, J., Sanchez, M., Lee, E., Hertzler, H., Luong, N., Mazzola, E., Finstein, B., Tamen, R., Brisbane, G., Nguyen, T., Paik, P., Chaft, J., Cheng, M., Khalil, H., Pih...> ;Journal of Thoracic Oncology. 2023 Dec 27 Diagnosis, testing, treatment, and outcomes among patients with advanced non-small cell lung cancer in the United States.
Yang, M., MacEwan, J., Boppudi, S., McClain, M., O'Hara, R., Paik, P.> ;Cancer Medicine. 2023 Dec 1- 2 citations
Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B.
Xiuning Le, Luis G Paz-Ares, Jan Van Meerbeeck, Santiago Viteri, Carlos Cabrera Galvez, Egbert F Smit, Marina Garassino, Remi Veillon, David Vicente Baz, Jose Fuentes ...> ;Cell Reports. Medicine. 2023 Nov 21 - Join now to see all
Journal Articles
Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
Paul K Paik, Xiuning Le, The New England Journal of MedicinePD-L1 Expression, Tumor Mutational Burden, and Response to Immunotherapy in Patients with MET Exon 14 Altered Lung Cancers
G J Riely, J Dienstag, C Mrad, J K Sabari, M G Kris, K C Arbour, D F Halpenny, N Rekhtman, R Chen, A J Plodkowski, P K Paik, B T Li, I Bergagnini, M D Offin, C M Rudin..., Annals of OncologyYES1 Amplification Is a Mechanism of Acquired Resistance to EGFR Inhibitors Identified by Transposon Mutagenesis and Clinical Genomics
Emmet J Jordan, Helena A Yu, Yelena Y Janjigian, Mark G Kris, Paul K Paik, Jamie E Chaft, Lu Wang, Gregory J Riely, Proceedings of the National Academy of Sciences
Lectures
Targeting NFE2L2/KEAP1 mutations in advanced NSCLC with the TORC1/2 inhibitor TAK-228.
2019 ASCO Annual Meeting - 6/1/2019Phase II study of tepotinib in NSCLC patients with METex14 mutations.
2019 ASCO Annual Meeting - 6/1/2019Targeting NFE2L2 mutations in advanced squamous cell lung cancers with the TORC1/2 inhibitor TAK228.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Authored Content
Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping MutationsMay 2020
Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping MutationsMay 2020
Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping MutationsMay 2020
Press Mentions
MET Mutation Inhibitor Associated with Tumor Reductions in NSCLCJune 26th, 2020
Paik Explains the Rationale for the Second-Line Standard for Patients with Squamous NSCLCMay 17th, 2019
OncLive® Hosts State of Science Summit™ on Advanced Non-Small Cell Lung CancerApril 5th, 2018
- Join now to see all
Hospital Affiliations
Insurance Accepted
Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS California PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPOGHI PPO
Great West PPO
Humana ChoiceCare Network PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO- Please verify your coverage with the provider's office directly when scheduling an appointment
